Loading...
OTCM
RHHBF
Market cap381bUSD
Oct 20, Last price  
479.43
Name

Roche Holding AG

Chart & performance

D1W1MN
OTCM:RHHBF chart
P/E
—
P/S
—
EPS
16.17
Vol. 1Y
—
Shs. 5Y
-1.48%
Rev. 5Y
1.07%
Div Yld LY
—
Div Yld TTM
—
Revenues
61.52b
-1.41%
42,041,000,00046,133,000,00045,617,000,00049,051,000,00047,473,000,00042,531,000,00045,499,000,00048,612,000,00049,866,000,00050,403,000,00052,636,000,00055,746,000,00059,497,000,00063,751,000,00058,323,000,00062,801,000,00065,814,000,00060,441,000,00062,395,000,00061,516,000,000
Net income
12.88b
+55.61%
7,880,000,0009,761,000,0008,969,000,0007,784,000,0008,666,000,0009,343,000,0009,539,000,00011,164,000,0009,332,000,0008,863,000,0009,576,000,0008,633,000,00010,500,000,00013,497,000,00014,295,000,00013,930,000,00012,421,000,00011,498,000,0008,277,000,00012,880,000,000
CFO
17.83b
-11.27%
10,329,000,00011,728,000,00012,177,000,00016,877,000,00014,342,000,00012,954,000,00015,005,000,00015,772,000,00015,930,000,00015,251,000,00015,001,000,00018,024,000,00019,979,000,00022,385,000,00018,160,000,00020,569,000,00017,890,000,00016,095,000,00020,094,000,00017,830,000,000
Dividend
Mar 13, 202612.4084 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Founded in 1896 and headquartered in Basel, Switzerland, Roche Holding AG is a global enterprise active in both the pharmaceutical and diagnostics sectors. Its extensive operations cover numerous countries, including Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium, alongside other international markets. The company's pharmaceutical division develops and provides therapies addressing a broad spectrum of medical conditions. These include cancer (oncology), neurological disorders, infectious diseases, immunological conditions, cardiovascular and metabolic issues, ophthalmological ailments, and respiratory illnesses. Furthermore, its product portfolio extends to treatments for anemia, dermatological problems, hemophilia, inflammatory and autoimmune diseases, and conditions related to organ transplantation. Within its diagnostics business, Roche provides a range of in vitro tests designed for identifying various diseases, such as cancer, diabetes, COVID-19, hepatitis, and human papillomavirus, among others. Complementing this, it also furnishes essential diagnostic instruments and chemical reagents. A significant research collaboration is in place with Synlogic, Inc., aimed at discovering a novel synthetic biotic treatment for inflammatory bowel disease (IBD).

Related entities

Subsidiaries (7)
ROCHE CATALYST INVESTMENTS LTD.
Roche Finance Europe B.V.
ROCHE FINANCIAL INVESTMENTS LTD.
Roche Financial Management Ltd.
ROCHE PHARMHOLDING B.V.
Roche Re AG
SAPAC CORPORATION, LTD.

Key people

Non-Executive Chairman of the Board · since 2023
Thomas Schinecker
Chief Executive Officer, Member of the Corporate Executive Committee · since 2023
Non-Executive Independent Vice Chairman of the Board
Alan Hippe
Chief Financial Officer, Member of the Corporate Executive Committee · since 2025
Teresa Graham
Member of the Corporate Executive Committee, Chief Executive Officer of Roche Pharmaceuticals · since 2023
Matt Sause
Member of the Corporate Executive Committee, Chief Executive Officer of Roche Diagnostics · since 2023
Cristina Wilbur
Member of the Corporate Executive Committee, Chief People Officer · since 2016
Chief Digital Technology Officer, Member of the Executive Committee · since 2025
Pascale Schmidt
Chief Compliance Officer · since 2020
Claudia Boeckstiegel
Member of the Enlarged Corporate Executive Committee, General Counsel · since 2020
Levi Garraway
Member of the Enlarged Corporate Committee, Head - Global Product Development and Chief Medical Officer · since 2023
Silke Hoernstein
Member of the Enlarged Corporate Executive Committee, Head - Corporate Strategy and Sustainability, Secretary to the Corporate Executive Committee · since 2023
Aviv Regev
Member of the Enlarged Corporate Executive Committee, Head - Genentech Research and Early Development (gRED) · since 2020
Barbara Schaedler
Member of the Enlarged Corporate Executive Committee, Head - Group Communications · since 2024
Boris Zaitra
Member of the Enlarged Corporate Executive Committee, Head - Corporate Business Development · since 2024
Joerg Duschmale
Non-Executive Independent Director · since 2020
Patrick Frost
Non-Executive Independent Director · since 2020
Non-Executive Independent Director · since 2017
Akiko Iwasaki
Non-Executive Independent Director · since 2023
Richard Lifton
Non-Executive Independent Director · since 2015
IPO date
May 04, 2001
Employees
103,613
Domiciled in
CH
Incorporated in
CH
Headquarters & legal address
Grenzacherstr. 124
Basel, BS 4058
CH
Other language
Roche Holding Ltd
Other language
Roche Holding SA

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT